The Effect of Medical cannabis Sativa on Opioid Use and Addiction

Cannabis Medical Australia, also known by the term “medical cannabis”, is cannabis and cannabinoids that are prescribed by doctors to patients with various ailments. The active ingredient in this type of cannabis is THC, which is a psychoactive substance found in the cannabis plant. Some countries, such as the USA, Canada, and Australia, prohibit smoking or ingesting marijuana. However, medical cannabis is legal in Uruguay and other countries. The active ingredients found in medical cannabis include THC, which induces a state of euphoria in the patient and relieves him/her of the disease; CBD, which is an antiseptic; and hashish or delta-9-tetrahydrocannabinol, which can be used to treat severe and debilitating diseases like glaucoma, nausea, cancer and seizures.

Hashish and delta-9-tetrahydrocannabinol were found to be most effective in treating glaucoma, and in reducing or eliminating the side effects of chemotherapy in the case of patients who are undergoing chemotherapy. Many countries have passed laws allowing medical cannabis to be used. Patients suffering from debilitating diseases such as cancer or AIDS should be able to use medical cannabis. CBD oil and medical cannabis are more effective than pharmaceutical drugs. The recommended dose of medical cannabis is two square decinos per day, which can be taken once or twice daily, depending on the recommendation of the patient’s doctor.

Two new prescription drugs in the form of nabilone and tetrahydrocannabinol (THC) have been approved by the FDA for use in the treatment of cancer and chemotherapy. The European Medicines Agency (EMA), announced in May 2021 that the first joint-venture clinical study involving two substances with the potential to treat serious diseases had been approved. The two substances are synthetic Cannabidiol and nabilone.

Both substances are made from plants, so FDA could reject them due to their psychoactive effects. Both substances were tested in controlled clinical trials. The results showed that they both have positive effects on anxiety-related disorders and posttraumatic stress disorder. Patients who received either CBD or Nabilone for post-traumatic stress disorder symptoms showed significant improvement in their symptoms, according to clinical trials. A meta-analysis by experts from the University of California San Francisco (UCSF), and the National Institute on Drug Abuse, (NIDA) confirmed this evidence.

Cannabidiol’s effectiveness is due to the fact that it doesn’t contain any psychoactive substances. It has not been shown to have any adverse effects on humans. Cannabidiol is reported to be the first new substance in centuries that does not display a “high” like the psychoactive substances present in cannabis, thereby facilitating rapid onset of action and profound relaxation of the patient. Nabilone, on the other hand, may also relieve anxiety and tension, but it is not psychoactive. These reports indicate that scientists believe cannabis is a better choice for treating patients suffering from anxiety and post-traumatic stress disorder.

Medical cannabis has been controversially studied for its effectiveness in reducing opioid addiction and use. Based on the studies reviewed above, the experts noted that chronic use of opioids can lead to overuse, withdrawal, and addiction in some patients, which can worsen symptoms and create more problems for the patient. When looking at the total participants of the studies, it is apparent that those who opted to take medical cannabis showed a reduction in opioid use and addiction, while the placebo group showed no significant change. This supports the notion that medical cannabis can help reduce abuse and addiction, while not necessarily eliminating the possibility of future opioid use or dependence. This supports the idea of medical cannabis being able to reduce the risk and burden of substance abuse in chronic patients.

Based on the findings from the systematic review and meta-analysis, it appears that medical marijuana laws may be effective in reducing overall opioid use and addiction, which have significant societal and economic impact. However, researchers caution that the impact might be limited if laws were implemented at the national level and regulated at the federal level. Some laws, for example, may not distinguish between black market and medical cannabis users. This would make cannabis more accessible to young people, who are most vulnerable to opioid abuse. To reduce opioid addiction and increase opioid use, the system should include a comprehensive framework that regulates and taxes cannabis at the national level.

From an organizational perspective, developing an evidence base supporting the efficacy of medical marijuana needs a holistic approach, including both data analysis and qualitative research methodology. Researchers suggest future research that will focus on cannabis’ effectiveness in treating chronic pain, nausea and depression. Future studies should also be done to determine the relationship between marijuana use, rates of substance abuse and dependence, as well as the relationship between marijuana addiction and cannabis use. Future studies should be done to assess the health and social impacts of medical cannabis and marijuana usage/recreational cannabis among adolescents. Future studies should also be done to assess the impact of legalized cannabis on landlords of children with certain developmental disorders.